Phage Therapy: Using Viruses to Combat Antibiotic-Resistant Bacteria

Phage therapy employs bacteriophages—viruses that infect and kill specific bacteria—as a targeted antimicrobial strategy. Renewed interest due to antibiotic resistance crisis.

Mechanism

1. Phage binds specific receptors on target bacterium.
2. Injects genome; hijacks host machinery to replicate.
3. Lysis releases progeny phages → infect neighboring bacteria (self-amplifying).
4. Phages cleared by immune system after bacteria eliminated.

Key Advantages

• Narrow Host Range: Infects specific strains/species → spares microbiome.
• Overcomes Resistance: Phages evolve; can target antibiotic-resistant strains (MRSA, CRE, Pseudomonas, Acinetobacter).
• Biofilm Penetration: Depolymerases degrade EPS matrix.
• Low Toxicity: No eukaryotic cell receptors; minimal side effects.
• Synergy with Antibiotics: Combined use reduces resistance emergence.

Clinical Applications

• Chronic infections: diabetic foot ulcers, prosthetic joint infections, cystic fibrosis lung infections, UTIs, osteomyelitis.
• Compassionate use (expanded access) for multidrug-resistant (MDR) infections failing standard therapy.
• Phage cocktails (broadened spectrum) vs. personalized (matched to patient isolate).

Challenges

• Regulatory: no FDA-approved phage products; IND required.
• Manufacturing: GMP production, stability, endotoxin removal.
• Host range limitation: need diagnostics for matching.
• Immune neutralization: antibodies may reduce efficacy on repeat dosing.
• Bacterial resistance to phages: occurs but manageable with cocktails.

Current Status

Phase I/II trials ongoing (e.g., Pseudomonas in CF, Staph prosthetic joints). Phage therapy centers emerging (US, Belgium, Georgia, Poland). Not yet standard care but promising for MDR infections.